These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31304571)

  • 1. Renal Function Estimates and Dosing of Direct Oral Anticoagulants in Stroke Patients with Atrial Fibrillation: An Observational Study.
    Chen YT; Lin HJ
    Acta Neurol Taiwan; 2018 Jun; 27(2)():39-44. PubMed ID: 31304571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparisons of effectiveness and safety between on-label dosing, off-label underdosing, and off-label overdosing in Asian and non-Asian atrial fibrillation patients treated with rivaroxaban: a systematic review and meta-analysis of observational studies.
    Chan YH; Chan CY; Chen SW; Chao TF; Lip GYH
    Europace; 2023 Oct; 25(10):. PubMed ID: 37738425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential Effect of Substituting Estimated Glomerular Filtration Rate for Estimated Creatinine Clearance for Dosing of Direct Oral Anticoagulants.
    Schwartz JB
    J Am Geriatr Soc; 2016 Oct; 64(10):1996-2002. PubMed ID: 27549687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DOAC Dosing Discordance Using Different Estimates of Kidney Function and Outcomes.
    Bhalodia NJ; White EM; Achanta A; Cheng J; Deri CR; Stahl K; Heiney H; Marchionda O; Iasella CJ; Coons JC
    J Clin Pharmacol; 2023 Sep; 63(9):1061-1066. PubMed ID: 37178305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Off-Label Dosing of Direct Oral Anticoagulants Among Inpatients With Atrial Fibrillation in the United States.
    Sandhu A; Kaltenbach LA; Chiswell K; Shimoga V; Ashur C; Pribish A; Fonarow GC; Piccini JP; Ho PM; Varosy PD; Hess PL
    Circ Cardiovasc Qual Outcomes; 2023 Dec; 16(12):e010062. PubMed ID: 37929603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry.
    Sato T; Aizawa Y; Fuse K; Fujita S; Ikeda Y; Kitazawa H; Takahashi M; Okabe M
    J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):3280-3288. PubMed ID: 30121155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
    Fox KA; Piccini JP; Wojdyla D; Becker RC; Halperin JL; Nessel CC; Paolini JF; Hankey GJ; Mahaffey KW; Patel MR; Singer DE; Califf RM
    Eur Heart J; 2011 Oct; 32(19):2387-94. PubMed ID: 21873708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
    Borne RT; O'Donnell C; Turakhia MP; Varosy PD; Jackevicius CA; Marzec LN; Masoudi FA; Hess PL; Maddox TM; Ho PM
    BMC Cardiovasc Disord; 2017 Sep; 17(1):236. PubMed ID: 28865440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study.
    López-Gálvez R; Rivera-Caravaca JM; Anguita Sánchez M; Sanmartín Fernández M; Rafols C; Pérez-Cabeza AI; Barón Esquivias G; Lekuona Goya I; Vázquez Rodríguez JM; Cosín Sales J; Arribas Ynsaurriaga F; Barrios V; Freixa-Pamias R; Marín F
    Eur J Clin Invest; 2022 Sep; 52(9):e13788. PubMed ID: 35395094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation.
    Manzano-Fernández S; Andreu-Cayuelas JM; Marín F; Orenes-Piñero E; Gallego P; Valdés M; Vicente V; Lip GY; Roldán V
    Rev Esp Cardiol (Engl Ed); 2015 Jun; 68(6):497-504. PubMed ID: 25457087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Renal Function on Dosing of Non-Vitamin K Antagonist Direct Oral Anticoagulants Among Patients With Nonvalvular Atrial Fibrillation.
    Shrestha S; Baser O; Kwong WJ
    Ann Pharmacother; 2018 Feb; 52(2):147-153. PubMed ID: 28856898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Recent Acute Heart Failure.
    Andreu-Cayuelas JM; Pastor-Pérez FJ; Puche CM; Mateo-Martínez A; García-Alberola A; Flores-Blanco PJ; Valdés M; Lip GY; Roldán V; Manzano-Fernández S
    Rev Esp Cardiol (Engl Ed); 2016 Feb; 69(2):134-40. PubMed ID: 26607030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.
    Albert NM
    Heart Lung; 2014; 43(1):48-59. PubMed ID: 24373340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation.
    Yao X; Tangri N; Gersh BJ; Sangaralingham LR; Shah ND; Nath KA; Noseworthy PA
    J Am Coll Cardiol; 2017 Nov; 70(21):2621-2632. PubMed ID: 29169468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variability in Nonvitamin K Oral Anticoagulant Dose Eligibility and Adjustment According to Renal Formulae and Clinical Outcomes in Patients With Atrial Fibrillation With and Without Chronic Kidney Disease: Insights From ORBIT-AF II.
    Yao RJR; Holmes DN; Andrade JG; Levin A; Piccini JP; Fordyce CB
    J Am Heart Assoc; 2023 Mar; 12(6):e026605. PubMed ID: 36892077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discrepancies between the use of MDRD-4 IDMS and CKD-EPI equations, instead of the Cockcroft-Gault equation, in the determination of the dosage of direct oral anticoagulants in patients with non-valvular atrial fibrillation.
    Pérez Cabeza AI; Chinchurreta Capote PA; González Correa JA; Ruiz Mateas F; Rosas Cervantes G; Rivas Ruiz F; Valle Alberca A; Bravo Marqués R
    Med Clin (Barc); 2018 Feb; 150(3):85-91. PubMed ID: 28739270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Ntaios G; Papavasileiou V; Makaritsis K; Vemmos K; Michel P; Lip GYH
    Stroke; 2017 Sep; 48(9):2494-2503. PubMed ID: 28716982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.